Common Pediatric Usage and Dosage of Nivolumab:
Recommended dose of nivolumab monotherapy:
|
Indications |
Dosage |
Duration |
|
Unresectable or metastatic melanoma |
For pediatric patients weighing ≥40 kg: Once every two weeks, 240 mg each time, intravenous infusion over
30 minutes. or Once every four weeks, 480 mg each time, intravenous infusion over
30 minutes. |
Patients were treated until disease progression or unacceptable
toxicity. |
|
For pediatric patients weighing ≥40 kg: Once every two weeks, 3 mg/kg each time, intravenous infusion over
30 minutes. or Once every four weeks, 6 mg/kg each time, intravenous infusion
over 30 minutes. |
||
|
Adjuvant therapy for melanoma |
For pediatric patients weighing ≥40 kg: Once every two weeks, 240 mg each time, intravenous infusion over
30 minutes. or Once every four weeks, 480 mg each time, intravenous infusion over
30 minutes. |
Patients were treated until disease progression or unacceptable
toxicity, but not longer than one year. |
|
For pediatric patients weighing ≥40 kg: Once every two weeks, 3 mg/kg each time, intravenous infusion over
30 minutes. or Once every four weeks, 6 mg/kg each time, intravenous infusion
over 30 minutes. |
||
|
Microsatellite instability-high (MSI-H) or mismatch
repair-deficient (dMMR) metastatic colorectal cancer |
For pediatric patients weighing ≥40 kg: Once every two weeks, 240 mg each time, intravenous infusion over
30 minutes. or Once every four weeks, 480 mg each time, intravenous infusion over
30 minutes. |
Patients were treated until disease progression or unacceptable
toxicity. |
|
For pediatric patients weighing ≥40 kg: Once every two weeks, 3 mg/kg each time, intravenous infusion over
30 minutes. |
Recommended doses of nivolumab when used in combination with other drugs:
|
Indications |
Dosage |
Duration |
|
Unresectable or metastatic melanoma |
Once every three weeks, 1 mg/kg each time, intravenous infusion
over 30 minutes, combined with ipilimumab 3 mg/kg. |
Combination therapy with ipilimumab. Use up to four times or until
unacceptable toxicity occurs, whichever comes first. |
|
For pediatric patients weighing ≥40 kg: Once every two weeks, 240 mg each time, intravenous infusion over
30 minutes. or Once every four weeks, 480 mg each time, intravenous infusion over
30 minutes. Combined treatment with ipilimumab 3 mg/kg. |
After completing 4 combination treatments, single-agent therapy
was used until disease progression or unacceptable toxicity occurred. |
|
|
For pediatric patients weighing ≥40 kg: Once every two weeks, 3 mg/kg each time, intravenous infusion over
30 minutes. or Once every four weeks, 6 mg/kg each time, intravenous infusion
over 30 minutes. |
||
|
Microsatellite instability-high (MSI-H) or mismatch
repair-deficient (dMMR) metastatic colorectal cancer |
Once every three weeks, 3 mg/kg each time, intravenous infusion
over 30 minutes, combined with ipilimumab 1 mg/kg. |
Combined treatment with ipilimumab for four doses. |
|
Pediatric patients 12 years and older weighing ≥40 kg: Once every two weeks, 240 mg each time, intravenous infusion over
30 minutes. or Once every four weeks, 480 mg each time, intravenous infusion over
30 minutes. Combined treatment with ipilimumab 1 mg/kg. |
After completing 4 combination treatments, single-agent therapy
was used until disease progression or unacceptable toxicity occurred. |
|
|
Pediatric patients 12 years and older weighing ≥40 kg: Once every two weeks, 3 mg/kg each time, intravenous infusion over
30 minutes. Combined treatment with ipilimumab 1 mg/kg. |
Preparation method of Nivolumab injection.
Nivolumab is generally diluted with 0.9% sodium chloride injection or 5% glucose injection to prepare an infusion solution with a concentration of 1 mg/ml to 10 mg/ml.
